SG Americas Securities LLC Acquires 1,341 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK)

SG Americas Securities LLC raised its holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 20.2% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 7,988 shares of the biotechnology company’s stock after buying an additional 1,341 shares during the quarter. SG Americas Securities LLC’s holdings in Anika Therapeutics were worth $181,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. BlackRock Inc. boosted its position in shares of Anika Therapeutics by 2.1% during the third quarter. BlackRock Inc. now owns 2,459,181 shares of the biotechnology company’s stock valued at $58,527,000 after purchasing an additional 49,994 shares in the last quarter. Trigran Investments Inc. grew its stake in Anika Therapeutics by 22.7% in the third quarter. Trigran Investments Inc. now owns 2,217,019 shares of the biotechnology company’s stock worth $41,303,000 after purchasing an additional 410,390 shares during the period. Vanguard Group Inc. grew its stake in Anika Therapeutics by 1.2% in the third quarter. Vanguard Group Inc. now owns 987,368 shares of the biotechnology company’s stock worth $23,499,000 after purchasing an additional 12,125 shares during the period. Dimensional Fund Advisors LP grew its stake in Anika Therapeutics by 1.9% in the first quarter. Dimensional Fund Advisors LP now owns 978,300 shares of the biotechnology company’s stock worth $28,096,000 after purchasing an additional 18,554 shares during the period. Finally, State Street Corp grew its stake in Anika Therapeutics by 16.4% in the first quarter. State Street Corp now owns 929,498 shares of the biotechnology company’s stock worth $23,340,000 after purchasing an additional 130,930 shares during the period. 91.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ANIK shares. Stephens reaffirmed an “equal weight” rating and issued a $22.00 price target on shares of Anika Therapeutics in a research note on Thursday, March 14th. StockNews.com raised Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, March 14th. Finally, Barrington Research upped their price target on Anika Therapeutics from $29.00 to $37.00 and gave the stock an “outperform” rating in a research note on Thursday, March 14th.

Anika Therapeutics Trading Down 2.4 %

NASDAQ ANIK opened at $25.00 on Monday. Anika Therapeutics, Inc. has a 12 month low of $16.54 and a 12 month high of $28.87. The stock has a market cap of $371.25 million, a P/E ratio of -4.42, a P/E/G ratio of 2.23 and a beta of 0.76. The stock’s fifty day moving average price is $25.08 and its 200-day moving average price is $22.63.

Anika Therapeutics (NASDAQ:ANIK) last released its earnings results on Wednesday, March 13th. The biotechnology company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.20. Anika Therapeutics had a negative return on equity of 2.10% and a negative net margin of 49.60%. The firm had revenue of $42.97 million for the quarter, compared to analysts’ expectations of $41.51 million. As a group, analysts forecast that Anika Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.